Company Category: Diagnostics

BioProduction by Sekisui offers CDMO services for the biopharmaceutical industry. Our UK facility has over 40 years fermentation and purification experience with proteins. Our microbial expression and process optimization together with our production experience helps smooth technical transfer and process scale up. We have process and analytical development capabilities for enzymes, plasmids, antibody fragments and other proteins. We are completing a $19M cGMP manufacturing expansion for drug substance manufacturing in 2024. We are co-exhibiting with Sekisui America Corporation, the regional HQ of global chemical manufacturer Sekisui Chemical, located in the United States. They work on developing solutions for the life science industry, with a focus on cell and gene therapy. Products include cell culture consumables such as state-of-the-art cell culture media and scaffolds. Chemically defined scaffold (CDS) can be used for the serum-free culture of pluripotent stem cells (iPSCs, ESCs, MSCs and so on). It is a synthetic polymer that can be stored at room temperature, pre-coated on a variety of surfaces and can be adapted to automated culture equipment. It can establish a safe and stable cell culture process and can lead to reduction in total cell culture cost. We are looking for partners in the field of cell and gene therapy such as academic organizations, pharmaceutical companies and automated bioreactor manufacturers who can act as joint development partners in adapting our products for their pipeline. | BioProduction by SEKISUI – A Specialized CDMO within the SEKISUI Medical Group BioProduction by SEKISUI is the biomanufacturing CDMO division of SEKISUI Diagnostics, part of the globally recognized SEKISUI Medical Group.BioProduction by SEKISUI describes SEKISUI’s contract service offering as a microbial fermentation focused CDMO with over 40 years of expertise in microbial biomanufacturing. We specialize in microbial fermentation, protein purification, and downstream processing for enzymes, recombinant proteins, ligands, antibody fragments, and plasmids. With experience in E. coli, Pichia pastoris, Bacillus, Streptococcus, Streptomyces, fungi, and yeast, we provide seamless process transfer and scale-up to meet diverse biopharmaceutical needs. Our UK-based facility features fermentation capacities ranging from 2L to 5,000L, advanced chromatography techniques, and lyophilization capabilities. While cGMP capacity expansion for clinical-grade drug substance manufacturing is in progress, we adhere to ISO 9001 standards, ISO 8 cleanroom classifications, and environmental safety regulations, ensuring quality and reliability. Driven by Kaizen-based continuous improvement and a zero-emissions sustainability commitment, BioProduction by SEKISUI partners with global leaders to deliver scalable, high-quality biomanufacturing solutions. Learn more at bioproduction-sekisui.com. SEKISUI CHEMICAL Group has been driving innovation since 1947. Today, we’re committed to developing cell culture solutions that make cell culture more reliable, scalable, and efficient. Our flagship product, Ceglu™, is a chemically defined, synthetic matrix that provides a stable, feeder-free environment for stem cells (iPSCs, ESCs, MSCs). Designed for consistency and ease of use, Ceglu™ reduces variability and offers the convenience of room-temperature storage. Ceglu™ is available in two formats: pre-coated culture plates for immediate use and a coating solution that can be applied to automated culture systems and bioreactors for seamless large-scale production. With a focus on advancing regenerative medicine, SEKISUI collaborates with industry leaders to deliver innovative solutions that meet the evolving needs of the cell and gene therapy field and help achieve shared goals. Learn more at https://www.sekisui-cell.jp/en/